Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial

Rita Murri, Adriana Ammassari, Patrizio Pezzotti, Antonella Cingolani, Andrea De Luca, Federico Pallavicini, Rita Grillo, Andrea Antinori

Research output: Contribution to journalArticle

Abstract

We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial. In total, 244 patients were randomized: 122 were assigned to CTX and 122 to DP. In the cohort, 22 bacteremia, 63 pneumonia, and 39 sinusitis/otitis cases were observed. Incidence rates of bacteremia, pneumonia, and sinusitis/otitis as well as the 2-year probability of remaining free from any bacterial infection were not significantly different between the two groups. At multivariate analysis, the risks of developing bacteremia and pneumonia were found to be independently increased by the use of a central venous catheter (hazard ratio [HR], 4.48; p <.05 and HR, 4.13; p <.01, respectively) and by hospitalization (HR, 28.82; p <.05 and HR, 10.15; p <.05, respectively). In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume27
Issue number1
Publication statusPublished - May 1 2001

Keywords

  • Bacterial infections
  • Cotrimoxazole
  • Pneumocystis carinii
  • Primary prophylaxis

ASJC Scopus subject areas

  • Virology
  • Immunology

Fingerprint Dive into the research topics of 'Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial'. Together they form a unique fingerprint.

  • Cite this